Yazar "Yozgat, Ahmet" seçeneğine göre listele
Listeleniyor 1 - 7 / 7
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Beliefs about medicines and adherence to treatment in Turkish patients with inflammatory bowel disease(AVES, 2022) Can, Güray; Yozgat, Ahmet; Tezel, Ahmet; Ünsal, Gülbin; Soylu, Ali RızaBackground: Although studies are investigating the perception and beliefs about treatment and adherence to treatment in different societies related to inflammatory bowel disease, there are no studies on this subject in Turkish people with different sociocultural structures. In our study, we aimed to evaluate the beliefs about treatment and its effect on adherence to treatment in the Turkish population with inflammatory bowel disease. Methods: In the study, the Medication Adherence Report Scale and Beliefs about Medicines Scale scales were used to evaluate the treatment compliance and perception and beliefs about treatment. Characteristics that could affect treatment compliance were evaluated by statistical analysis. Results: A total of 253 patients, 167 with ulcerative colitis and 86 with Crohn's disease, were included in the study. The non-adherence rate to the treatment was found as 41.9% in ulcerative colitis and 24.4% in Crohn's disease (P =.006). Intentional (29.3% in ulcerative colitis and 16.3% in Crohn's disease [P =.031] and unintentional non-adherence to treatment (28.1% in ulcerative colitis, 16.3% in Crohn's disease [P =.037] were significantly higher in ulcerative colitis than in Crohn's disease. Female gender (odds ratio = 2.59, P =.005), low education level (odds ratio = 4.8, P =.015), distal involvement in ulcerative colitis (P =.014), and thoughts about the disease would last too soon in Crohn's disease (odds ratio = 4.17, P =.049) were risk factors for non-adherence to treatment. Conclusion: The negative perception of treatment in inflammatory bowel disease affects adherence to the treatment. Considering some social factors that affect adherence to the treatment and taking measures to enhance the adherence to treatment will increase the success of treatment.Öğe ÇÖLYAK HASTALIĞINDA FİBROMİYALJİ SIKLIĞI VE FİBROMİYALJİNİN HASTALAR ÜZERİNE ETKİSİNİN DEĞERLENDİRİLMES(2021) Yozgat, Ahmet; Can, Güray; Gürler, Müjgan; Kahveci, Samet; Yildirim, MehmetAMAÇ: Çölyak hastalığı, gluten ilişkili bir enteropati olmakla birlikte malabsorbsiyona bağlı bütün vücudu etkileyebilen bir hastalıktır. Diğer yandan antijen maruziyeti sebebiyle kronik inflamasyona da zemin hazırlamaktadır. Kronik inflamasyonun vücutta sistemik etkilerinin olduğu bilinmektedir. Çölyak hastalığının sistemik etkileri farklı mekanizmalar üzerinden fibromiyalji sendromunu (FMS) tetikliyor olabilir. Çalışmamızın amacı Çölyak hastalarında FMS prevalansını belirlemek ve FMS’nin Çölyak hastaları üzerindeki etkisini değerlendirmektir. GEREÇ VE YÖNTEM: Çalışmaya 1 Şubat-10 Haziran 2019 tarihleri arasında Gastroenteroloji kliniğimize başvuran 24 Çölyak hastası (7 aktif, 17 Çölyak diyeti altında) ve 20 kontrol gönüllü olarak dahil edildi. FMS tanısı için 2010 American College of Rheumatology kriterleri kullanıldı. WSPI (yaygın ağrı indeksi), SSS (somatik semptom ağırlık skoru) ve toplamından FMS skoru hesaplandı. Bütün katılımcılara fibromiyalji etki anketi uygulandı. Veriler istatistiksel olarak karşılaştırıldı. BULGULAR: Çölyak hastaları ve kontrol grubunda FMS sıklığı birbirleriyle karşılaştırıldığında anlamlı farklılık saptanmadı; Çölyak hastalarında %12,5, gönüllü kontrol grubunda %5 (p: 0,61). Kadın ve erkeklerdeki FMS sıklığı benzerdi. Gruplar arasında WSPI, SSS ve FMS skorları açısından anlamlı fark yoktu. FMS etki skalası skorları yönünden FMS olanlar ile olmayanlar karşılaştırıldığında gönüllü kontrol grubunda anlamlı fark yoktu (23,9±18,8 ve 21,5±0; p: 0,90). Çölyak hastalığı olanlarda, FMS etki skoru FMS olanlarda olmayanlara göre daha yüksek olmasına rağmen anlamlılık düzeyine ulaşmamıştır (51,9±25,5 ve 28,5±17,7; p: 0,25). SONUÇ: Türk toplumunda Çölyak hastalarında FMS sıklığını gösteren ilk çalışmadır. Normal popülasyona göre Çölyak hastalığında FMS sıklığı artmamaktadır. Çölyak hastalığında aktivitenin FMS üzerine etkisi yoktur. FMS tanısı olan Çölyak hastalarında olmayanlara göre hayat kalitesi daha çok etkilenmektedir. Daha geniş bir popülasyonda yapılacak çalışmalara ihtiyaç vardır.Öğe Evaluation of epicardial adipose tissue and carotid intima-media thickness as a marker of atherosclerosis in patients with inflammatory bowel disease(ARÁN EDICIONES, S.L., 2021) Ekmen, Nergiz; Can, Güray; Yozgat, Ahmet; Can, Hatice; Bayraktar, Muhammed Fatih; Demirkol, Muhammed Emin; Kayhan, Meral Akdoğan; Sasani, HadiBackground and aim: this study aimed to compare carotid intima media (CIMT) and epicardial adipose tissue (EAT) measurements, which are considered as markers for the detection of early atherosclerosis in healthy controls and inflammatory bowel disease (IBD) cases. Methods: a total of 60 IBD patients (25 Crohn’s disease and 35 ulcerative colitis) and 60 healthy patients (as a control group) were included in the study. The measurements of CIMT and EAT were performed using echocardiography and ultrasonography, respectively. Statistical analysis was used to determine the relationship between the parameters. Results: the thickness of bilateral (right and left) CIMT and EAT were significantly higher in IBD than in the control group (p < 0.05). There was a positive correlation between EAT and bilateral (right and left) CIMT in IBD patients (p < 0.05). Conclusion: IBD is associated with an increased thickness of EAT and CIMT. Chronic inflammation in IBD may increase the risk of atherosclerotic heart disease. Thus, only measur ing the thickness of EAT and CIMT can be used as an objec tive, easy, simple, affordable, non-invasive and accessible assessment method in order to screen for this riskÖğe Gamma-glutamyl-transferase may predict COVID-19 outcomes in hospitalised patients(Wiley-Hindawi, 2021) Kasapoğlu, Benan; Yozgat, Ahmet; Tanoğlu, Alpaslan; Can, Güray; Sakin, Yusuf SerdarAim In this study, we aimed to define the predictive role of liver function tests at admission to the hospital in outcomes of hospitalised patients with COVID-19. Material and Method In this multicentric retrospective study, a total of 269 adult patients (>= 18 years of age) with confirmed COVID-19 who were hospitalised for the treatment were enrolled. Demographic features, complete medical history and laboratory findings of the study participants at admission were obtained from the medical records. Patients were grouped regarding their intensive care unit (ICU) requirements during their hospitalisation periods. Results Among all 269 participants, 106 were hospitalised in the ICU and 66 died. The patients hospitalised in ICU were older than patients hospitalised in wards (P = .001) and expired patients were older than alive patients (P = .001). Age, elevated serum D-dimer, creatinine and gamma-glutamyl transferase (GGT) levels at admission were independent factors predicting ICU hospitalisation and mortality in COVID-19 patients. Conclusion In conclusion, in hospitalised patients with COVID-19, laboratory data on admission, including serum, creatinine, GGT and d-dimer levels have an important predictive role for the ICU requirement and mortality. Since these tests are readily available in all hospitals and inexpensive, some predictive formulas may be calculated with these parameters at admission, to define the patients requiring intensive care.Öğe Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19(Scientific Technical Research Council Turkey-TÜBİTAK, 2021) Yozgat, Ahmet; Kasapoğlu, Benan; Can, Güray; Tanoğlu, Alpaslan; Sakin, Yusuf Serdar; Yalçın, Kadir Serkan; Gürler, MüjganBackground and aim: The aim of this study is to evaluate whether the long-term (≥4 weeks) use of proton pump inhibitors (PPIs) is a risk factor for intubation requirement and mortality in patients hospitalized for COVID-19. Materials and methods: In this multicentric retrospective study, a total of 382 adult patients (≥18 years of age) with confirmed COVID-19 who were hospitalized for treatment were enrolled. The patients were divided into two groups according to the periods during which they used PPIs: the first group included patients who were not on PPI treatment, and the second group included those who have used PPIs for more than 4 weeks. Results: The study participants were grouped according to their PPI usage history over the last 6 months. In total, 291 patients did not use any type of PPI over the last 6 months, and 91 patients used PPIs for more than 4 weeks. Older age (HR: 1.047, 95% CI: 1.026–1.068), current smoking (HR: 2.590, 95% CI: 1.334–5.025), and PPI therapy for more than 4 weeks (HR: 1.83, 95% CI: 1.06–2.41) were found to be independent risk factors for mortality. Conclusion: The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes for patients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19 treatment.Öğe Social stigmatization in Turkish patients with chronic hepatitis B and C(Ediciones Doyma, S.L., 2021) Yozgat, Ahmet; Can, Güray; Can, Hatice; Ekmen, Nergiz; Akyol, Taner; Kasapoğlu, Benan; Kekilli, MuratBackground and aim: Viral hepatitis is the most important cause of chronic hepatitis worldwide. Stigmatization is defined as a feeling of rejection and isolation of patients by society due to illness. There are no studies on chronic viral hepatitis in the literature in English, which has its own religious and socio-cultural structure. In our study, we aimed to investigate the presence of social stigmatism and psychosocial effects on patients with different stages of chronic viral hepatitis B and C. Methods: Forty-five patients with chronic hepatitis C and 114 patients with chronic hepatitis B were enrolled in the study. Berger's scale was used for stigmatization, composed of 40 four-point Likert items that have four subscales: personalized stigma, disclosure, negative self-image, and public attitude. Stigma score ranges between one and four. Stigma is accepted as present if the overall score is above two. Results: Overall the mean stigma scores were 1.97 ± 0.58 and 2.14 ± 0.57 for chronic hepatitis B and C, respectively. There was stigma in 47.4% of the patients with chronic hepatitis B, and 60% of the patients with chronic hepatitis C. Being male was the risk factor on overall stigma, disclosure and public attitude in chronic hepatitis C. Living in an urban setting was the risk factor on negative self-image in chronic hepatitis C and on personalized stigma and disclosure in chronic hepatitis B. Conclusions: To the best of our knowledge, this is the first study that provides qualitative information about chronic hepatitis-related stigma. Stigmatization is a major problem in Turkey and worldwide. We believe that increasing the knowledge of the patients and society by teaching about the transmission routes of the disease and focusing on vaccination studies will prevent stigmatization.Öğe Ulcerative colitis may be a risk factor for sensorineural hearing loss(2021) Yozgat, Ahmet; Gürler, MüjganIntroduction: Inner ear involvement of inflammatory bowel disease (IBD), which causes sensorineural hearing loss (SNHL) is acute and bilateral and arises in a short period of weeks to months in the active period of the disease. We aimed to determine the frequency of SNHL in patients with UC and CD and to evaluate the relationship between audiological features and clinical findings in IBD. Material and Method: The present study included 53 IBD patients and 20 healthy control patients who were followed up in the gastroenterology outpatient clinic of Abant Izzet Baysal University Hospital between January and May 2020 and accepted to participate in the study. Tympanometry, otoscopy, and audiometry examinations were performed. Results: There was no significant difference in terms of gender and age between the IBD and control groups. While there was no significant difference in air and bone conduction in both ears in patients with CD, there was a significant difference between both conductions in UC (p: 0.0001 in the left ear, p: 0.004 in the right ear). SNHL was detected in 45.2% (n:14) of UC patients and 13.6% (n:3) of CD patients in audiometry. Three of our UC patients had moderate, one had moderately severe, and one had profound hearing loss. Conclusion: SNHL has been detected in a significant number of UC patients. Also, the hearing functions deteriorate significantly as the age of the patients and the duration of the disease increases. UC patients with a long-term disease or older patients should be evaluated for SNHL.
